As marijuana legalization has spread to new states and regions, the regulatory framework of the industry has struggled to adapt. How to ensure product safety via scientific testing has been a popular debate, and some legal markets have mandated testing for cannabis producers and retailers.
Ganjapreneur, a cannabis industry publication focused on business news and culture, recently published an interview with Dr. Michelle Sexton of PhytaLab about her take on cannabis testing regulations.
Dr. Sexton founded PhytaLab in 2010, and she has also served as a consultant to the Washington State Liquor Control Board on the implementation of I-502, the state’s bill which led to the legalization of marijuana for recreational use. She is a member of the International Cannabinoid Research Society, the International Association for Cannabinoid Medicines, and the Society of Cannabis Clinicians, and she is also an avid surfer and rock climber.
In the interview, Sexton explains how the lack of federal recognition of legal cannabis markets has made scientific research very difficult. "Due to the federal status, crowd-sourced science has virtually replaced clinical research, being 'loosely' conducted without the usual controls or theoretical frameworks," Dr. Sexton said.